ALG.APV-527 First-in-human Study
NCT05934539
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
56
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
ALG.APV-527
Sponsor
Aptevo Therapeutics
Collaborators
[object Object]